AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36075585 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and severe tinnitus
Number of subjects: 429
Study 36075585 — intervention group
Group type: EXPERIMENTAL
Intervention: ARHL and tinnitus
Number of subjects: 429
Study 36075585 — intervention group
Group type: EXPERIMENTAL
Intervention: ARHL severity
Number of subjects: 429
Study 36075585 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus severity
Number of subjects: 429
Study 36075585 — intervention group
Group type: EXPERIMENTAL
Intervention: ARHL with tinnitus
Number of subjects: 429
Study 36075643 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) for aSMR
Number of subjects: 53
Study 36075643 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter edge-to-edge repair (TEER) for ventricular secondary mitral regurgitation (vSMR)
Number of subjects: 53
Study 36075643 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) for aSMR and vSMR
Number of subjects: 53
Study 36075914 — intervention group
Group type: EXPERIMENTAL
Intervention: lete-cel (NY-ESO-1 TCR T cells)
Number of subjects: 45
Study 36076044 — intervention group
Group type: EXPERIMENTAL
Intervention: ATOPE+ mHealth system
Number of subjects: 22
Study 36076054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0
Study 36076123 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) regimen
Number of subjects: 30
Study 36076205 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Assertive Community Treatment
Number of subjects: 329
Study 36076250 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Number of subjects: 24
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: Various wearable devices (21 devices total)
Number of subjects: 258
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn ActiGraph GT9X
Number of subjects: 258
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: All wearable technologies
Number of subjects: 258
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle and thigh devices
Number of subjects: 258
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-worn devices
Number of subjects: 258
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn devices
Number of subjects: 258
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed, wear location, and age
Number of subjects: 258
Study 36076265 — intervention group
Group type: EXPERIMENTAL
Intervention: Very slow walking speeds (0.8 to 3.2 km/h)
Number of subjects: 258
Study 36077617 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986158 (5 days on, 2 days off; 0.75-4.5 mg)
Number of subjects: 83
Study 36077617 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986158 (14 days on, 7 days off; 2.0-3.0 mg)
Number of subjects: 83
Study 36077617 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986158 (7 days on, 14 days off; 2.0-4.5 mg)
Number of subjects: 83
Study 36077617 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986158 (all schedules)
Number of subjects: 83
Study 36077617 — intervention group
Group type: COMPARATOR
Intervention: BMS-986158 (schedules A and C)
Number of subjects: 83
Study 36077723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 67
Study 36077869 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sarcoma and COVID-19
Number of subjects: 281
Study 36078407 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist girth-based equations (e.g., relative fat mass)
Number of subjects: 0
Study 36078407 — intervention group
Group type: EXPERIMENTAL
Intervention: New models including waist girth
Number of subjects: 0
Study 36078888 — intervention group
Group type: EXPERIMENTAL
Intervention: Inodilators (dobutamine and milrinone)
Number of subjects: 496
Study 36078888 — intervention group
Group type: COMPARATOR
Intervention: No inodilators
Number of subjects: 496
Study 36081609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body medicine (MBM) program, weekly 6-h session for 10 weeks
Number of subjects: 102
Study 36081609 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received an initial 90-min workshop and started the intervention 9 months later
Number of subjects: 102
Study 36081814 — intervention group
Group type: EXPERIMENTAL
Intervention: EA plus high-dose DCPA (4 mg)
Number of subjects: 40
Study 36081814 — intervention group
Group type: COMPARATOR
Intervention: EA only
Number of subjects: 40
Study 36081814 — intervention group
Group type: COMPARATOR
Intervention: EA plus low-dose DCPA (2 mg)
Number of subjects: 40
Study 36081814 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 40
Study 36081814 — intervention group
Group type: COMPARATOR
Intervention: EA at ST36 and GB34
Number of subjects: 40
Study 36082134 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 400
Study 36082252 — intervention group
Group type: EXPERIMENTAL
Intervention: QD DOAC
Number of subjects: 956
Study 36082252 — intervention group
Group type: EXPERIMENTAL
Intervention: BID DOAC
Number of subjects: 956
Study 36082252 — intervention group
Group type: COMPARATOR
Intervention: DOAC (QD and BID)
Number of subjects: 956
Study 36082269 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis treatment for 24 months
Number of subjects: 0
Study 36082554 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy (NHA) prior to radical prostatectomy (RP)
Number of subjects: 371
Study 36082554 — intervention group
Group type: COMPARATOR
Intervention: Up-front radical prostatectomy (RP)
Number of subjects: 371
Study 36082616 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO-4578, an antagonist of prostaglandin E, specific dosage and duration not available
Number of subjects: 0
Study 36082616 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36082948 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanghai Stroke Service System (4S) intervention
Number of subjects: 92395
Study 36083035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (anthracycline-containing regimens)
Number of subjects: 131
Study 36083035 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced stage, elevated LDH, ECOG-PS ≥2
Number of subjects: 131
Study 36083035 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated LDH, ECOG-PS ≥2
Number of subjects: 131
Study 36083129 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 30
Study 36083129 — intervention group
Group type: EXPERIMENTAL
Intervention: AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 30
Study 36083129 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pembrolizumab and AVD
Number of subjects: 30
Study 36083129 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic alterations in 9p24.1 and PD-L1 positivity
Number of subjects: 30
Study 36083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Back pain intervention (not specified, observational study)
Number of subjects: 452
Study 36083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity count (CC)
Number of subjects: 452
Study 36083174 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity burden (CB)
Number of subjects: 452
Study 36083313 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus autologous dendritic cell vaccine
Number of subjects: 19
Study 36083313 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 36083436 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance exercise training (RET) for 6 weeks
Number of subjects: 2
Study 36083436 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements before RET
Number of subjects: 2
Study 36083516 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) for 48 weeks
Number of subjects: 48
Study 36083608 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based ANC
Number of subjects: 1761
Study 36083608 — intervention group
Group type: COMPARATOR
Intervention: Routine individual ANC
Number of subjects: 1761
Study 36083982 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma selenium (Se) concentrations
Number of subjects: 935
Study 36083982 — intervention group
Group type: EXPERIMENTAL
Intervention: Second tertile of baseline plasma Se (74.5 to < 89.4 μg/L)
Number of subjects: 935
Study 36083982 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of baseline plasma Se (89.4 to <150 μg/L)
Number of subjects: 935
Study 36084356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster A (high irritability and obsessive-compulsive behaviors)
Number of subjects: 105
Study 36084356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster B (apathetic group)
Number of subjects: 105
Study 36084356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster C (patients in earlier stages)
Number of subjects: 105
Study 36084356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster D (patients in earlier stages with increasing burden)
Number of subjects: 105
Study 36084395 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg, administered intravenously every 3 weeks
Number of subjects: 2185
Study 36084395 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 2185
Study 36084396 — intervention group
Group type: EXPERIMENTAL
Intervention: eprenetapopt (4.5 g/day IV on days 1-4) plus pembrolizumab (200 mg IV on day 3 in each 21-day cycle)
Number of subjects: 40
Study 36085009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 17
Study 36085059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin A
Number of subjects: 0
Study 36085059 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nasal continuous positive airway pressure
Number of subjects: 0
Study 36085059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 36085092 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for pyloric stenosis
Number of subjects: 310
Study 36085337 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMs questionnaires (Euro Quality 5 Dimensions 3L, EQ-5D-3L, Euro-Quality-Visual-Analytic-Score, EQ-VAS, Hip disability and Osteoarthritis Outcome Score, HOOS-PS) administered pre-operatively, at 6 months, and at 12 months after surgery.
Number of subjects: 991
Study 36085337 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMs trajectories at 6 and 12 months after HA.
Number of subjects: 991
Study 36085716 — intervention group
Group type: EXPERIMENTAL
Intervention: SSVEP-based neurofeedback training using a portable augmented-reality EEG interface
Number of subjects: 5
Study 36085716 — intervention group
Group type: EXPERIMENTAL
Intervention: SSVEP indices
Number of subjects: 5
Study 36086773 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 93
Study 36086773 — intervention group
Group type: COMPARATOR
Intervention: Lymphoscintigraphy
Number of subjects: 93
Study 36086773 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index >30 kg/m2
Number of subjects: 93
Study 36086817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib and dasatinib supplementation with unedited CD7 CAR T cells
Number of subjects: 0
Study 36086817 — intervention group
Group type: EXPERIMENTAL
Intervention: Unedited CD7 CAR T cells
Number of subjects: 0
Study 36086862 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 8
Study 36086862 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive placebo (DP)
Number of subjects: 8
Study 36086862 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) and Deceptive placebo (DP)
Number of subjects: 8
Study 36087148 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic collection of different biomarkers through electronic case report forms
Number of subjects: 0
Study 36087148 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data collection
Number of subjects: 0
Study 36087148 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring impact of iRBD on quality of life and sleep quality
Number of subjects: 0
Study 36087148 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation assessment between phenoconversion, cognitive performance, and loss of normal muscle atony during REM sleep
Number of subjects: 0
Study 36087148 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of clinical, biological, neurophysiological, neuropsychological, and imaging biomarkers
Number of subjects: 0
Study 36087148 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of vPSG criteria for RBD diagnosis
Number of subjects: 0
Study 36087223 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 1537
Study 36087223 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment for GERD
Number of subjects: 1537
Study 36087223 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral preservation and gastropexy
Number of subjects: 1537
Study 36087223 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to LRYGB
Number of subjects: 1537
Study 36087565 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-item short-form of the CD-Quest
Number of subjects: 0
Study 36087565 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-item ultra-short-form of the CD-Quest
Number of subjects: 0
Study 36087795 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-CNN on noncontrast images
Number of subjects: 270
Study 36087795 — intervention group
Group type: COMPARATOR
Intervention: DCE CT imaging
Number of subjects: 270
Study 36087795 — intervention group
Group type: COMPARATOR
Intervention: PET with CT scan imaging
Number of subjects: 270
Study 36087795 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP-CNN on contrast images
Number of subjects: 270
Study 36087863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Number of subjects: 6
Study 36088136 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive AI device
Number of subjects: 21
Study 36088136 — intervention group
Group type: COMPARATOR
Intervention: No AI assistance (Control)
Number of subjects: 21
Study 36088618 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 60
Study 36088618 — intervention group
Group type: COMPARATOR
Intervention: MRI
Number of subjects: 60
Study 36088618 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and MRI
Number of subjects: 60
Study 36088802 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-Athletic Shoulder Test (M-AST)
Number of subjects: 20
Study 36088802 — intervention group
Group type: COMPARATOR
Intervention: Athletic Shoulder Test (AST)
Number of subjects: 20
Study 36088907 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Induced Acute Kidney Injury (DI-AKI) risk prediction models
Number of subjects: 0
Study 36088907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical adjudication of AKI etiology
Number of subjects: 0
Study 36088907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality prospective dataset
Number of subjects: 0
Study 36088907 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods (e.g., least absolute shrinkage and selection operator regression, advanced machine learning techniques)
Number of subjects: 0
Study 36088907 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-defined dataset of clinically adjudicated cases
Number of subjects: 0
Study 36088949 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HDL cholesterol
Number of subjects: 155724
Study 36088949 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 155724
Study 36088949 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with a PURE score of 4 or lower
Number of subjects: 155724
Study 36088949 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural and psychosocial risk factors
Number of subjects: 155724
Study 36089112 — intervention group
Group type: EXPERIMENTAL
Intervention: GST-HG131, a novel HBV antigen inhibitor
Number of subjects: 0
Study 36089112 — intervention group
Group type: COMPARATOR
Intervention: RG7834
Number of subjects: 0
Study 36089234 — intervention group
Group type: EXPERIMENTAL
Intervention: CD24-Gold Nanocomposite
Number of subjects: 60
Study 36089234 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 60
Study 36089578 — intervention group
Group type: EXPERIMENTAL
Intervention: UV1 vaccination and ipilimumab treatment
Number of subjects: 12
Study 36089621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 82
Study 36089621 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy (APT) + Oral anticoagulation (OAC)
Number of subjects: 82
Study 36089621 — intervention group
Group type: COMPARATOR
Intervention: DAPT + OAC
Number of subjects: 82
Study 36089621 — intervention group
Group type: COMPARATOR
Intervention: Single APT + OAC
Number of subjects: 82
Study 36089784 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Volume PEG (4L)
Number of subjects: 228
Study 36089784 — intervention group
Group type: COMPARATOR
Intervention: Low-Volume PEG (2L)
Number of subjects: 228
Study 36089784 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 228
Study 36090504 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO 2012 guidelines for CKD classification
Number of subjects: 123807
Study 36090504 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing albuminuria
Number of subjects: 123807
Study 36090504 — intervention group
Group type: EXPERIMENTAL
Intervention: Declining baseline eGFR
Number of subjects: 123807
Study 36090504 — intervention group
Group type: EXPERIMENTAL
Intervention: Median number of eGFR tests per year post-index
Number of subjects: 123807
Study 36090504 — intervention group
Group type: EXPERIMENTAL
Intervention: Median number of UACR tests per year post-index
Number of subjects: 123807
Study 36090504 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO 2012 guidelines
Number of subjects: 123807
Study 36090603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully vaccinated (n=74)
Number of subjects: 8554
Study 36090603 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially vaccinated (n=198)
Number of subjects: 8554
Study 36090603 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 8554
Study 36090637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin (Pem-Cis); 500 mg/m2 of pemetrexed administered for four cycles in 99 patients (94.3%).
Number of subjects: 105
Study 36091159 — intervention group
Group type: EXPERIMENTAL
Intervention: Retifanlimab plus carboplatin-paclitaxel
Number of subjects: 300
Study 36091159 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel
Number of subjects: 300
Study 36091254 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory and low fermentable oligo, di, and monosaccharides and polyols (FODMAP) diet
Number of subjects: 46
Study 36091254 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 36091711 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation (ASV) 1.1
Number of subjects: 30
Study 36091711 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of FiO2
Number of subjects: 30
Study 36092320 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib and proton therapy
Number of subjects: 9
Study 36092332 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab + FOLFIRI
Number of subjects: 362
Study 36092362 — intervention group
Group type: EXPERIMENTAL
Intervention: MV-s-NAP, a novel oncolytic measles virus strain
Number of subjects: 0
Study 36092827 — intervention group
Group type: EXPERIMENTAL
Intervention: AMR infections
Number of subjects: 2043
Study 36092827 — intervention group
Group type: COMPARATOR
Intervention: AMS infections
Number of subjects: 2043
Study 36092968 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable prediction models for AECOPD occurrence
Number of subjects: 246
Study 36092968 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable prediction models for AECOPD severity
Number of subjects: 246
Study 36093129 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 0
Study 36093342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of high-dose rate brachytherapy (HDB) 20 Gy
Number of subjects: 33
Study 36093738 — intervention group
Group type: EXPERIMENTAL
Intervention: Elezanumab 50-1,600mg IV and 150mg subcutaneous
Number of subjects: 67
Study 36093738 — intervention group
Group type: EXPERIMENTAL
Intervention: Elezanumab 150mg, 600mg, and 1,800mg
Number of subjects: 67
Study 36093738 — intervention group
Group type: EXPERIMENTAL
Intervention: Elezanumab up to 1,800mg
Number of subjects: 67
Study 36093738 — intervention group
Group type: EXPERIMENTAL
Intervention: Elezanumab 1,800mg IV
Number of subjects: 67
Study 36093738 — intervention group
Group type: EXPERIMENTAL
Intervention: Elezanumab
Number of subjects: 67
Study 36093977 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 223
Study 36093977 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric Patients
Number of subjects: 223
Study 36093977 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia (SKZ) subgroup
Number of subjects: 223
Study 36093977 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality Disorders (PDs)
Number of subjects: 223
Study 36093977 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive-Compulsive Disorder (OCD) patients
Number of subjects: 223
Study 36093977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lockdown period (T1)
Number of subjects: 223
Study 36094142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir + rilpivirine LA
Number of subjects: 24
Study 36094508 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 611
Study 36094508 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 611
Study 36094508 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DTG and EFV
Number of subjects: 611